160 related articles for article (PubMed ID: 17119852)
1. A novel loss-of-function mutation in TP53 in an endometrial cancer cell line and uterine papillary serous carcinoma model.
Liu Z; Wan G; Heaphy C; Bisoffi M; Griffith JK; Hu CA
Mol Cell Biochem; 2007 Mar; 297(1-2):179-87. PubMed ID: 17119852
[TBL] [Abstract][Full Text] [Related]
2. Models representing type I and type II human endometrial cancers: Ishikawa H and Hec50co cells.
Albitar L; Pickett G; Morgan M; Davies S; Leslie KK
Gynecol Oncol; 2007 Jul; 106(1):52-64. PubMed ID: 17490735
[TBL] [Abstract][Full Text] [Related]
3. TP53 Mutational Spectrum in Endometrioid and Serous Endometrial Cancers.
Schultheis AM; Martelotto LG; De Filippo MR; Piscuglio S; Ng CK; Hussein YR; Reis-Filho JS; Soslow RA; Weigelt B
Int J Gynecol Pathol; 2016 Jul; 35(4):289-300. PubMed ID: 26556035
[TBL] [Abstract][Full Text] [Related]
4. Endometrial glandular dysplasia: a putative precursor lesion of uterine papillary serous carcinoma. Part II: molecular features.
Liang SX; Chambers SK; Cheng L; Zhang S; Zhou Y; Zheng W
Int J Surg Pathol; 2004 Oct; 12(4):319-31. PubMed ID: 15494858
[TBL] [Abstract][Full Text] [Related]
5. Loss of p53 function in uterine papillary serous carcinoma.
Kovalev S; Marchenko ND; Gugliotta BG; Chalas E; Chumas J; Moll UM
Hum Pathol; 1998 Jun; 29(6):613-9. PubMed ID: 9635683
[TBL] [Abstract][Full Text] [Related]
6. Endometrial glandular dysplasia: a newly defined precursor lesion of uterine papillary serous carcinoma. Part I: morphologic features.
Zheng W; Liang SX; Yu H; Rutherford T; Chambers SK; Schwartz PE
Int J Surg Pathol; 2004 Jul; 12(3):207-23. PubMed ID: 15306933
[TBL] [Abstract][Full Text] [Related]
7. Allelic expression imbalance of TP53 mutated and polymorphic alleles in head and neck tumors.
Ganci F; Conti S; Fontemaggi G; Manciocco V; Donzelli S; Covello R; Muti P; Strano S; Blandino G; Spriano G
OMICS; 2011 Jun; 15(6):375-81. PubMed ID: 21348641
[TBL] [Abstract][Full Text] [Related]
8. Discovery of TP53 splice variants in two novel papillary urothelial cancer cell lines.
Koch A; Hatina J; Rieder H; Seifert HH; Huckenbeck W; Jankowiak F; Florl AR; Stoehr R; Schulz WA
Cell Oncol (Dordr); 2012 Aug; 35(4):243-57. PubMed ID: 22669776
[TBL] [Abstract][Full Text] [Related]
9. EGFR isoforms and gene regulation in human endometrial cancer cells.
Albitar L; Pickett G; Morgan M; Wilken JA; Maihle NJ; Leslie KK
Mol Cancer; 2010 Jun; 9():166. PubMed ID: 20579378
[TBL] [Abstract][Full Text] [Related]
10. Endometrial glandular dysplasia with frequent p53 gene mutation: a genetic evidence supporting its precancer nature for endometrial serous carcinoma.
Jia L; Liu Y; Yi X; Miron A; Crum CP; Kong B; Zheng W
Clin Cancer Res; 2008 Apr; 14(8):2263-9. PubMed ID: 18369088
[TBL] [Abstract][Full Text] [Related]
11. Damage-inducible intragenic demethylation of the human TP53 tumor suppressor gene is associated with transcription from an alternative intronic promoter.
Blackburn J; Roden DL; Ng R; Wu J; Bosman A; Epstein RJ
Mol Carcinog; 2016 Dec; 55(12):1940-1951. PubMed ID: 26676339
[TBL] [Abstract][Full Text] [Related]
12. Amifostine enhancement of the anti-cancer effects of paclitaxel in endometrial cancer is TP53-dependent.
Luo W; Wu F; Elmaoued R; Beck BB; Fischer E; Meng X; Leslie KK; Dai D
Int J Oncol; 2010 Nov; 37(5):1187-94. PubMed ID: 20878066
[TBL] [Abstract][Full Text] [Related]
13. PPP2R1A mutations are common in the serous type of endometrial cancer.
Nagendra DC; Burke J; Maxwell GL; Risinger JI
Mol Carcinog; 2012 Oct; 51(10):826-31. PubMed ID: 21882256
[TBL] [Abstract][Full Text] [Related]
14. Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study.
Vang R; Levine DA; Soslow RA; Zaloudek C; Shih IeM; Kurman RJ
Int J Gynecol Pathol; 2016 Jan; 35(1):48-55. PubMed ID: 26166714
[TBL] [Abstract][Full Text] [Related]
15. RNA interference-mediated silencing of the p53 tumor-suppressor protein drastically increases apoptosis after inhibition of endogenous fatty acid metabolism in breast cancer cells.
Menendez JA; Lupu R
Int J Mol Med; 2005 Jan; 15(1):33-40. PubMed ID: 15583825
[TBL] [Abstract][Full Text] [Related]
16. Opposite alterations of DNA methyltransferase gene expression in endometrioid and serous endometrial cancers.
Xiong Y; Dowdy SC; Xue A; Shujuan J; Eberhardt NL; Podratz KC; Jiang SW
Gynecol Oncol; 2005 Mar; 96(3):601-9. PubMed ID: 15721400
[TBL] [Abstract][Full Text] [Related]
17. Adenovirus-mediated expression of p53 or p21 in a papillary serous endometrial carcinoma cell line (SPEC-2) results in both growth inhibition and apoptotic cell death: potential application of gene therapy to endometrial cancer.
Ramondetta L; Mills GB; Burke TW; Wolf JK
Clin Cancer Res; 2000 Jan; 6(1):278-84. PubMed ID: 10656459
[TBL] [Abstract][Full Text] [Related]
18. Utility of p16 expression for distinction of uterine serous carcinomas from endometrial endometrioid and endocervical adenocarcinomas: immunohistochemical analysis of 201 cases.
Yemelyanova A; Ji H; Shih IeM; Wang TL; Wu LS; Ronnett BM
Am J Surg Pathol; 2009 Oct; 33(10):1504-14. PubMed ID: 19623034
[TBL] [Abstract][Full Text] [Related]
19. Intra-tumor heterogeneity in TP53 null High Grade Serous Ovarian Carcinoma progression.
Mota A; Triviño JC; Rojo-Sebastian A; Martínez-Ramírez Á; Chiva L; González-Martín A; Garcia JF; Garcia-Sanz P; Moreno-Bueno G
BMC Cancer; 2015 Nov; 15():940. PubMed ID: 26620706
[TBL] [Abstract][Full Text] [Related]
20. Coexisting intraepithelial serous carcinomas of the endometrium and fallopian tube: frequency and potential significance.
Jarboe EA; Miron A; Carlson JW; Hirsch MS; Kindelberger D; Mutter GL; Crum CP; Nucci MR
Int J Gynecol Pathol; 2009 Jul; 28(4):308-15. PubMed ID: 19483636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
